Papaverine Injection Recall Issued Nationwide After Glass and Chemical Contamination Detected

FDA Announces Recall of Papaverine Hydrochloride Injection Over Safety Concerns

A nationwide recall has been issued for a specific batch of Papaverine Hydrochloride Injection after contamination with glass particles and paraformaldehyde was discovered. The recall affects a single lot of the injectable prescription medication that was distributed across the United States beginning in late September 2025.

According to the recall announcement published by the U.S. Food and Drug Administration (FDA), the presence of these contaminants poses potentially serious health risks if the medication is administered. Although no injuries or adverse reactions have been reported so far, healthcare providers and patients are being urged to stop using the affected product immediately.

Why the Papaverine Injection Was Recalled

American Regent Inc., the manufacturer of the medication, voluntarily recalled one lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single-dose vials after identifying visible particulate matter inside some vials. Laboratory testing identified the particles as glass and or paraformaldehyde.

Injecting contaminated medication can lead to complications ranging from localized irritation to life threatening medical emergencies. Small particles introduced into the bloodstream may obstruct blood vessels, reducing blood flow to critical organs such as the brain, heart, or lungs.

Medical experts warn that blocked blood vessels can increase the risk of serious conditions, including stroke, heart complications, pulmonary issues, or even death in severe cases.

What Is Papaverine Hydrochloride?

Papaverine Hydrochloride is a prescription medication that works by relaxing smooth muscle tissue and widening blood vessels. Doctors prescribe it for several medical conditions involving poor blood circulation and muscle spasms.

Some common uses include:

• Treating visceral muscle spasms.
• Improving blood circulation in certain conditions.
• Managing erectile dysfunction in select medical situations.

The medication is supplied as a sterile injectable solution and is typically administered under medical supervision.

Understanding the Potential Risks

The contamination involves two different materials, each carrying its own safety concerns.

Glass Particles

Glass fragments inside injectable medications are especially dangerous because they can enter the bloodstream during administration. Once circulating, these particles may:

• Damage blood vessels.
• Trigger inflammation.
• Block circulation.
• Cause tissue injury.
• Increase the risk of stroke or organ damage.

Paraformaldehyde

Paraformaldehyde is a solid form of formaldehyde commonly used in laboratory and industrial environments. It is not intended to be present in injectable medications.

If introduced into the body through injection, contaminated material may create additional health risks depending on the amount and location of exposure.

Patients at Greater Risk

While anyone receiving contaminated injections could experience complications, certain individuals face a higher level of risk.

According to American Regent, patients with pre existing cardiovascular or pulmonary diseases may be more vulnerable to severe outcomes if contaminated particles enter their bloodstream.

Healthcare providers are encouraged to carefully review inventory and discontinue use of the affected lot immediately.

Which Product Is Affected?

The recall applies only to one specific lot of Papaverine Hydrochloride Injection.

Affected product information includes:

• Product: Papaverine Hydrochloride Injection USP
• Strength: 60 mg/2 mL
• Package: Single dose vial
• Lot Number: 25202
• NDC: 0517-4002-25
• Expiration Date: November 30, 2026

No other lots were included in the recall announcement.

Has Anyone Been Harmed?

As of the recall announcement, American Regent reported that it had not received any confirmed reports of injuries or adverse events associated with the recalled medication.

Although this is reassuring, the absence of reported cases does not eliminate the potential risk. The recall was issued as a precautionary measure to prevent future harm.

Healthcare professionals are advised to remain vigilant for any unusual reactions in patients who may have received the affected medication.

What Should Healthcare Providers Do?

Hospitals, pharmacies, distributors, and medical facilities should immediately identify any affected inventory and remove it from use.

The manufacturer has instructed customers to either:

• Return the recalled product to the place of purchase.
• Properly dispose of the affected vials according to applicable procedures.

American Regent is also coordinating replacement and return arrangements with distributors and customers.

What Should Patients Do?

Patients who believe they may have received the recalled medication should contact their physician or healthcare provider for medical advice.

Individuals should not attempt to continue using any recalled injectable medication. If symptoms such as swelling, pain, breathing difficulty, chest pain, dizziness, or other unexpected reactions occur after receiving an injection, immediate medical attention should be sought.

Patients experiencing problems that may be related to the recalled product are encouraged to report their concerns to their healthcare provider.

Cause of the Contamination Remains Unknown

The recall notice did not explain how the glass particles or paraformaldehyde entered the affected production lot.

At this time, American Regent has not publicly identified the source of the contamination or whether manufacturing, packaging, or another factor contributed to the issue.

Regulatory agencies and the manufacturer may continue investigating the cause as part of standard quality assurance procedures.

Importance of Drug Quality Monitoring

Medication recalls play an important role in protecting public health. Pharmaceutical manufacturers regularly conduct quality testing and monitoring to detect defects before products cause widespread harm.

When contamination or manufacturing problems are discovered, voluntary recalls help remove affected products from circulation while healthcare providers receive updated guidance.

Patients should never ignore recall announcements involving prescription medications, especially injectable drugs, since they bypass many of the body's natural protective barriers.

Final Thoughts

The nationwide recall of Papaverine Hydrochloride Injection highlights the importance of pharmaceutical quality control and patient safety. Although no injuries have been reported, contamination with glass particles and paraformaldehyde presents a potentially serious risk if the medication is injected.

Healthcare providers should immediately stop using the affected lot and follow the manufacturer's return instructions. Patients who believe they may have received the recalled medication should consult their healthcare provider for guidance and report any unusual symptoms promptly.

Staying informed about medication recalls can help prevent avoidable complications and ensure patients receive safe and effective treatment.

Source: U.S. Food and Drug Administration (FDA) recall notice, American Regent Inc. recall announcement.

Disclaimer: This article is intended for informational and educational purposes only. It should not be considered medical advice, diagnosis, or treatment. If you have questions about a recalled medication or believe you may have received the affected product, consult your physician or another qualified healthcare professional immediately.